Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-125b lentivirus is an experimental gene therapy construct consisting of a lentiviral vector designed to deliver and enforce the expression of microRNA-125b (miR-125b). miR-125b is a small non-coding RNA that functions as a key regulator of hematopoietic stem cell (HSC) and leukemia stem cell (LSC) maintenance by modulating the translation and stability of various target mRNAs. In preclinical studies of acute myeloid leukemia (AML), the use of this lentiviral vector to over-express miR-125b has been shown to promote the expansion of LSCs and multi-lymphoid progenitors (MLP), suggesting its role as an oncomiR that enhances self-renewal. This tool is primarily used in research settings to investigate the molecular mechanisms of leukemogenesis and stem cell biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-125b lentivirus.